Related Experiment Video
Updated: Mar 19, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Development of Pancreatic Cancer: Targets for Early Detection and Treatment
Markus M Lerch1, Julia Mayerle, Ujjwal Mahajan
1Department of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Background:
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer death worldwide and compared to other malignancies its share in cancer mortality is expected to rise further. This is due to a lack of sensitive diagnostic tools that would permit earlier detection in a potentially curable stage and the very slow progress in finding effective drug treatments for pancreatic cancer.
Key Messages:
Aside from genetic predispositions and environmental agents, chronic pancreatitis is by far the greatest risk factor for PDAC. It also shares several etiological factors with pancreatic cancer and represents its most challenging differential diagnosis. Biomarkers that can distinguish between chronic pancreatitis and PDAC may therefore be suitable for the latter's early detection. Moreover, targeting the natural history of chronic pancreatitis would be one approach to prevent PDAC. Targeting tumor-cell signaling directly by interfering with receptor tyrosine kinases has shown some efficacy, although the results in clinical trials were less encouraging than for other cancers. Other compounds developed have targeted the formation of extracellular matrix around the tumor, the proteolytic activity in the tumor environment, histone deacetylases, hedgehog signaling and heat shock proteins, but none has yet found its way into routine patient care. Attempts to individualize treatment according to the tumor's somatic mutation profile are novel but so far impractical.
Conclusions:
Progress in the treatment of pancreatic cancer has been exceedingly slow and mostly dependent on improved pharmaceutical preparations or combinations of established chemotherapeutic agents. The promise of major breakthroughs implied in targeting tumor signal transduction events has so far not materialized.
Insights
Pancreatic cancer remains a deadly disease with slow treatment progress. Early detection through biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma is crucial for better outcomes.
Area of Science:
- Oncology
- Gastroenterology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality globally.
- Its mortality share is projected to increase due to limited diagnostic tools and slow therapeutic advancements.
- Current diagnostic methods lack sensitivity for early-stage detection, hindering curable treatment opportunities.
Purpose of the Study:
- To highlight the challenges in diagnosing and treating pancreatic cancer.
- To explore potential biomarkers for early detection by differentiating PDAC from chronic pancreatitis.
- To review current and novel therapeutic strategies for PDAC.
Main Methods:
- Review of existing literature on pancreatic cancer diagnosis and treatment.
- Analysis of risk factors, including chronic pancreatitis.
- Evaluation of targeted therapies and personalized medicine approaches.
Main Results:
- Chronic pancreatitis is a major risk factor and diagnostic challenge for PDAC.
- Biomarkers distinguishing chronic pancreatitis from PDAC are promising for early detection.
- Targeted therapies (e.g., receptor tyrosine kinases, hedgehog signaling) have shown limited clinical efficacy.
- Personalized treatment based on tumor mutation profiles is currently impractical.
Conclusions:
- Progress in pancreatic cancer treatment has been slow, relying on incremental improvements in chemotherapy.
- Novel therapeutic strategies targeting tumor signaling pathways have not yet yielded significant breakthroughs.
- Developing sensitive biomarkers and effective preventative strategies are critical for improving PDAC outcomes.
